Press release
Hutchinson-Gilford Progeria Syndrome Market Driven by Advancements in Gene Therapy and R&D Funding 2025-2033 | Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Ultragenyx Pharmaceutical Inc.
Global Hutchinson-Gilford progeria syndrome market reached US$ 102.1 billion in 2024 and is expected to reach US$ 207.21 billion by 2031, growing at a CAGR of 8.6% during the forecast period 2024-2031.Hutchinson-Gilford Progeria Syndrome Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/hutchinson-gilford-progeria-syndrome-market?ophp
Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare genetic disorder causing accelerated aging in children, typically linked to a mutation in the LMNA gene. The treatment market is niche but growing due to increased research into gene-targeted therapies, recent FDA approvals, and global advocacy efforts for early diagnosis and trial access.
Hutchinson-Gilford Progeria Syndrome Market Competitors Overview:
Eiger BioPharmaceuticals, Inc., The Progeria Research Foundation, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Ultragenyx Pharmaceutical Inc.
Important Industry Updates of 2023, 2024 and 2025:
✅ In May 2024, Sentynl Therapeutics acquired Zokinvy® (lonafarnib)-originally developed by Eiger-for up to $26 million, gaining control of the only FDA-approved HGPS therapy
✅ PRG Science & Technology began a Phase 2a trial for its oral candidate Progerinin in October 2024, receiving FDA approval to enroll patients for the study
Methodology and Scope
The Hutchinson-Gilford Progeria Syndrome Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hutchinson-gilford-progeria-syndrome-market?ophp
Hutchinson-Gilford Progeria Syndrome Market Segments Overview:
∎ By Treatment Type (Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), Low-Dose Aspirin, Physical and Occupational Therapy, Hearing Aids, Genetic Counseling, Others)
∎ By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others)
Regional Overview for Hutchinson-Gilford Progeria Syndrome Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=hutchinson-gilford-progeria-syndrome-market?ophp
The Report Covers:
➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.
People Also Ask:
➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hutchinson-Gilford Progeria Syndrome Market Driven by Advancements in Gene Therapy and R&D Funding 2025-2033 | Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Ultragenyx Pharmaceutical Inc. here
News-ID: 4108316 • Views: …
More Releases from DataM intelligence 4 Market Research LLP

Autonomous Data Platform Market to Reach USD 14.96 Billion by 2032, Report by Da …
Overview of the Autonomous Data Platform Market
The Autonomous Data Platform (ADP) market is witnessing rapid growth, driven by digital transformation and the increasing need for real-time data analytics. ADPs use Artificial Intelligence (AI) and Machine Learning (ML) to automate data management, enabling businesses to make faster, data-driven decisions while minimizing human intervention. These platforms enhance operational efficiency, reduce errors, and allow enterprises to focus on strategic initiatives. ADPs are increasingly…

Global 6G Technology Market to Reach USD 9.03 Billion by 2032, Report by DataM I …
Overview of the Global 6G Technology Market
The 6G technology market represents the next frontier in wireless communication, promising unprecedented advancements in speed, connectivity, and intelligence. Building upon the foundation laid by 5G, 6G aims to deliver peak data rates exceeding 1 terabit per second, ultra-low latency, and seamless integration of artificial intelligence (AI) and quantum-resistant encryption. These capabilities are set to revolutionize industries such as healthcare, automotive, manufacturing, and entertainment…

Spinal Muscular Atrophy Treatment Market to Reach USD 20.06 Billion by 2033, Rep …
Overview of the Spinal Muscular Atrophy Treatment Market
Spinal Muscular Atrophy (SMA) is a rare genetic disorder characterized by progressive muscle weakness, leading to severe physical disability and, in many cases, early death. The advent of innovative therapies has significantly altered the treatment landscape for SMA, offering hope for improved patient outcomes. Gene therapies, such as onasemnogene abeparvovec (Zolgensma), nusinersen (Spinraza), and risdiplam (Evrysdi), have demonstrated efficacy in increasing survival rates…

United States Prime Editing and CRISPR Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
Prime Editing and CRISPR Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031).
Key Development:
United States: Recent Industry Developments
✅ July 2025 - Prime Medicine announced an additional investment of up to $24 million from the Cystic Fibrosis Foundation to advance gene editing therapy targeting the G542X mutation, a prevalent cystic fibrosis-causing mutation with no current therapies.
✅ July 2025 - CRISPR…
More Releases for Progeria
Hutchinson-Gilford Progeria Syndrome Market Trends Point to Steady Growth Ahead, …
DelveInsight's "Hutchinson-Gilford Progeria Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hutchinson-Gilford Progeria Syndrome, historical and forecasted epidemiology as well as the Hutchinson-Gilford Progeria Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report delivers a detailed analysis of Hutchinson-Gilford Progeria Syndrome, covering revenue patterns, prevalence, and the treatment landscape. It provides…
Hutchinson-Gilford Progeria Syndrome Market Expected to Reach Rapid Growth by 20 …
Global Hutchinson-Gilford progeria syndrome market reached to reach at a significant CAGR during the forecast period 2024-2031.
Hutchinson-Gilford Progeria Syndrome Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive…
Hutchinson-Gilford Progeria Treatment Market Outlook, and Opportunity Analysis, …
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a…
Hutchinson-Gilford Progeria Treatment Market - Global Industry Insights, Trends, …
Hutchinson-Gilford progeria is a rare condition that affects about one in four million newborns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any…
Hutchinson-Gilford Progeria Treatment Market, Company Analysis and Forecast to 2 …
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a…
Hutchinson-Gilford Progeria Treatment Market - Trends, Outlook, and Opportunity …
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from the childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. The affected children develop a characteristic facial experience including prominent eyes, small chin, protruding ears, thin lips and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a…